In COVID-19 clinical update #104, Daniel Griffin reviews effectiveness of mRNA vaccines among children, number of children affected by disease, accuracy of rapid antigen tests, CDC guidance for prevention strategies, monoclonal antibody effectiveness, predicting progression to severe respiratory failure from pneumonia, risk of long COVID after two vaccine doses, and peripheral neuropathy in long COVID.
Click arrow to play
Download TWiV 872 (52 MB .mp3, 43 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Vaccine effectiveness 5-11 year olds (medRxiv) 11:29
- Vaccine effectiveness vs ED and UCE 5-12 year olds (MMWR) 13:52
- Children affected by COVID (Lancet) 19:57
- Accuracy of rapid antigen tests (medRxiv) 20:57
- COVID community levels (CDC) 23:21
- Therapeutics guidelines (WHO) 33:33
- Mortality among SOT (Clin Inf Dis) 40:23
- Long COVID after two vaccine doses (medRxiv) 41:09
- Peripheral neuropathy in COVID patients (Neurology) 45:05
- Letters read on TWiV 872 48:17
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to email@example.com
6:45 – Prof. Vincent had a good question – triple vaccinated get what? This *is* a concern for those 70, 80, and 90-year olds. I believe the CDC defines advanced age as something like a comorbidity or at-risk. What do triple vaccinated 70 year olds get?
What happened to 26:46-28 minutes when you are about to speak critically about cdc new metric? It’s a terrible shame if this is intentionally cut. This is the place we come to think and discuss things critically.
The missing audio is fixed, re-download to listen.